3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Brain Neoplasms
3
Neoplasms by Site
2
Neoplasms
2
Lymphoma, Large-Cell, Anaplastic
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms by Histologic Type
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Filgrastim
11
Temozolomide
9
Melphalan
9
Cyclophosphamide
9
Radiotherapy
7
Busulfan
7
Magnetic Resonance Spectroscopy
6
Rituximab
5
Psychiatric Rehabilitation
5
Methotrexate
5
Etoposide
5
Cytarabine
5
Carboplatin
5
sargramostim
4
fludarabine
4
etoposide phosphate
4
Thiotepa
4
Nivolumab
4
Methylprednisolone
4
Flow Cytometry
4
Alemtuzumab
4
Vincristine
3
Topotecan
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Pemetrexed
3
Granulocyte Colony-Stimulating Factor
3
Early Intervention, Educational
3
Drug Therapy
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
alectinib
×
CNS
×
Clear all
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled